Navigation Links
Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:10/1/2013

CORK, Ireland, Oct. 1, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announced that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place November 1 to 5 in Washington, D.C.

"Simeprevir's clinical profile has been characterized through a robust clinical development program including more than 3,700 patients," said Gaston Picchio, Disease Area Leader Hepatitis, Janssen. "The study results that will be presented at the AASLD Annual Meeting support the potential utility of simeprevir in a number of different hepatitis C patient populations."

Simeprevir was approved in Japan in September 2013 for the treatment of genotype 1 hepatitis C. In the U.S., the New Drug Application (NDA) filed by Janssen for simeprevir administered once daily in combination with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients was granted Priority Review designation by the Food and Drug Administration (FDA) in May. Simeprevir is also being studied in several interferon-free regimens using selected combinations of direct-acting antiviral agents with different mechanisms of action.

The data to be presented at the 2013 AASLD Annual Meeting include:

Poster Presentations: HCV Therapeutics: New Agents, Poster Hall, November 3, 8:00 a.m. - 5:30 p.m. (EST)

  • Simeprevir (TMC435) with peg-interferon alpha-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: Efficacy and safety in patient sub-populations in the PROMIS
    '/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
2. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
3. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
4. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
5. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
6. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
9. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
10. Bulgaria Launches Development of National Hepatitis Plan
11. Major Breakthrough in Hepatitis C Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Report Details ... brand new report shows you potential revenues to 2024, ... 208-page report provides 160 tables, charts, and graphs. Our ... in the prostate cancer therapeutics market, showing their prospects ... industry and the future market prospects. Our new study ...
(Date:9/23/2014)...   LabStyle Innovations Corp . (OTCQB: DRIO), ... announced that it has closed a $4.2 million ... stock and warrants.  No placement agent was used ... expects to secure net proceeds of approximately $4.1 ... intends to use the net proceeds from the ...
(Date:9/23/2014)... 23, 2014  Global Discovery Biosciences, a laboratory dedicated ... the biggest healthcare challenges, announces their collaboration with IPMD, ... test for the early detection of lung cancer. ... death. Typically, the symptoms and subsequent diagnosis of lung ... the chance of a cure has already passed. Early ...
Breaking Medicine Technology:The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 2The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 3The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 4The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 5LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5Global Discovery Biosciences Announces Collaboration with IPMD, Inc. to Develop Innovative Aptamer-Based Blood Test for the Early Detection of Lung Cancer 2
... THOUSAND OAKS, Calif., Nov. 10, 2010 Amgen Inc. ... of results from the first open-label study to compare ... therapies (SOC) in non-splenectomized adult patients with chronic immune ... in the New England Journal of Medicine ...
... -- HealthWarehouse.com, Inc . (OTC Bulletin ... retail mail-order pharmacy, announced today that it has placed ... debt with independent investors. The investment will ... while upgrading its technology infrastructure to keep pace with ...
Cached Medicine Technology:Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP 2Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP 3Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP 4Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP 5Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP 6Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP 7Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP 8Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP 9Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP 10Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP 11HealthWarehouse.com Places $3.3 Million in Preferred Stock and $1 Million in Convertible Debt 2HealthWarehouse.com Places $3.3 Million in Preferred Stock and $1 Million in Convertible Debt 3
(Date:9/23/2014)... Menopause can cause symptoms similar to ... women, menopause can trigger debilitating fluctuations in hormone ... major depressive disorder. These include intense feelings ... and fatigue. While hormone therapies are helpful ... cost make them an unsuitable treatment for many ...
(Date:9/23/2014)... Mirena IUD lawsuits ( http://www.themirenalawsuitcenter.com/ ) ... of the birth control device continue to mount in ... to court documents dated September 18th, an Iowa woman ... IUD outside of the uterus caused the device to ... now pending in the U.S. District Court, Northern District ...
(Date:9/23/2014)... 2014 Mel Frank, also known as ... and harvesting marijuana. He is perhaps one of the ... he’ll be leading a special elective course on growing ... pm at Oaksterdam University in Oakland, California. ... nomenclature, harvesting and manicuring, and identifying preflowers and outdoor ...
(Date:9/23/2014)... ZEPHYRHILLS, FL (PRWEB) September 23, 2014 ... opening of the newly renovated Women’s Health Center ... square feet of space, the specially designed center ... women in East Pasco County. The Women’s Health ... and pelvic floor health, labor and delivery through ...
(Date:9/23/2014)... PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS IN THE ... The National Institutes of Health is convening a Pathways ... on the long-term effectiveness and potential risks of opioids ... nation,s top experts in the field of pain control ... key NIH scientists who focus on pain related research. ...
Breaking Medicine News(10 mins):Health News:Pristiq Discounts Now Available from MedicationDiscountCard.com To Help Ease Menopause Symptoms 2Health News:Mirena IUD Lawsuit News: New Complaint Filed On Behalf of Iowa Woman Claims Mirena Migrated to Her Rectum, Bernstein Liebhard LLP Reports 2Health News:Mirena IUD Lawsuit News: New Complaint Filed On Behalf of Iowa Woman Claims Mirena Migrated to Her Rectum, Bernstein Liebhard LLP Reports 3Health News:Mirena IUD Lawsuit News: New Complaint Filed On Behalf of Iowa Woman Claims Mirena Migrated to Her Rectum, Bernstein Liebhard LLP Reports 4Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3
... (January, 13 2008) University of Minnesota researchers have created ... a process called whole organ decellularization, scientists from the University ... by taking dead rat and pig hearts and reseeding them ... published online in the January 13 issue of Nature Medicine., ...
... injected into ,skeleton, of animal organ was beating in ... -- An organ-building biotechnology that could create transplantable hearts ... important laboratory tests, researchers report. , The technique, called ... heart tissue, according to a report in the Jan. ...
... notMYkid, I,wouldn,t be here today," says James, a ClearChoices ... as long as I was at dinner each,night... they ... story,with kids today and prevent them from going through ... a partnership between Chrysler LLC and,Barrett- Jackson will allow ...
... Promise to Deliver ... 12 Hala Moddelmog, president and CEO of,Susan G. Komen ... end breast,cancer forever, today was recognized for her leadership in ... a ,High Heels in High,Places, award. The Trumpet Awards Foundation, ...
... Company Reaffirms Fiscal 2008 Revenue Guidance, FORT LAUDERDALE, ... today announced the resignation of Chief Financial,Officer Robert Hamilton. ... accepted the Chief Financial Officer position at a privately ... transitional,matters., The Company has retained a search firm ...
... N.C., Jan. 11 Today,s top-level,pharmaceutical companies devise ... will carry out the plan as early as ... pharmaceutical research firm, Best,Practices, LLC., As the ... invest people and money earlier in the product,research ...
Cached Medicine News:Health News:U of M researchers create beating heart in laboratory 2Health News:Biotechnology Builds a New Heart 2Health News:Biotechnology Builds a New Heart 3Health News:First in Nation: notMYkid Educational Center Is Now a Reality Thanks to a Partnership Between Chrysler, Barrett-Jackson and notMYkid 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3Health News:eDiets.com, Inc. Announces Resignation of Robert Hamilton, Chief Financial Officer 2Health News:eDiets.com, Inc. Announces Resignation of Robert Hamilton, Chief Financial Officer 3Health News:Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: